Erin Furr Stimming, MD, FAAN, FANA, McGovern Medical School, UTHealth, Houston, TX, discusses the available treatment options for motor and psychiatric symptoms in Huntington’s disease (HD), emphasizing the lack of approved medication for cognitive symptoms. Currently, there are three FDA-approved VMAT2 inhibitors: tetrabenazine, deutetrabenazine, and valbenazine. However, addressing psychiatric symptoms may require different medications. While progress has been made in treating psychiatric symptoms, cognitive symptoms remain a challenge. Dr Furr Stimming mentions an ongoing clinical trial evaluating the safety and efficacy of a medication for HD-related cognitive decline. The need for continued progress in disease modification and symptomatic relief is emphasized. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
